Shan Jiang; Shan Jiang

doi:10.46234/ccdcw2022.146

[1]

Biesecker LG. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet Med 2012;14(4):393-8. https://www.nature.com/articles/gim201178.https://www.nature.com/articles/gim201178

[2]

Green RC, Rehm HL, Kohane IS. Clinical genome sequencing. In: Ginsburg GS, Willard HF, editors. Genomic and personalized medicine. Amsterdam: Elsevier. 2013; p. 102-22. https://www.genomes2people.org/wp-content/uploads/2012/07/Green-Rehm-Kohane-ClinGenomeSequencing-2012.pdf.https://www.genomes2people.org/wp-content/uploads/2012/07/Green-Rehm-Kohane-ClinGenomeSequencing-2012.pdf

[3]

Mackley MP, Fletcher B, Parker M, Watkins H, Ormondroyd E. Stakeholder views on secondary findings in whole-genome and whole-exome sequencing: a systematic review of quantitative and qualitative studies. Genet Med 2017;19(3):283-93. https://www.nature.com/articles/gim2016109.https://www.nature.com/articles/gim2016109

[4]

Delanne J, Nambot S, Chassagne A, Putois O, Pelissier A, Peyron C, et al. Secondary findings from whole-exome/genome sequencing evaluating stakeholder perspectives. A review of the literature. Eur J Med Genet 2019;62(6):103529. https://www.sciencedirect.com/science/article/pii/S1769721218301228?casa_token=Io3N7hZWhLkAAAAA:meFnUB7PfjIoSphlvfdzTknEa7r9HHLqhISuUIVdHnVofaG6xUPAlQCEV1EDpncU9MluAbXQHQ.https://www.sciencedirect.com/science/article/pii/S1769721218301228?casa_token=Io3N7hZWhLkAAAAA:meFnUB7PfjIoSphlvfdzTknEa7r9HHLqhISuUIVdHnVofaG6xUPAlQCEV1EDpncU9MluAbXQHQ

[5]

Jiang S, Anis AH, Cromwell I, Mohammadi T, Schrader KA, Lucas J, et al. Health-care practitioners’ preferences for the return of secondary findings from next-generation sequencing: a discrete choice experiment. Genet Med 2020;22(12):2011-9. https://www.nature.com/articles/s41436-020-0927-x.https://www.nature.com/articles/s41436-020-0927-x

[6]

Townsend A, Adam S, Birch PH, Lohn Z, Rousseau F, Friedman JM. “I want to know what's in Pandora’s Box”: comparing stakeholder perspectives on incidental findings in clinical whole genomic sequencing. Am J Med Genet Part A 2012;158A(10):2519-25. https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.a.35554?casa_token=39aw0eVQBnMAAAAA%3At1Rdqen1t9pkeewc6eWLJjhP2AoIkR7xnLAnAygaoBeT333PQzb6A9RdRXm0p2YjuuSxuWpkNlXiiw.https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.a.35554?casa_token=39aw0eVQBnMAAAAA%3At1Rdqen1t9pkeewc6eWLJjhP2AoIkR7xnLAnAygaoBeT333PQzb6A9RdRXm0p2YjuuSxuWpkNlXiiw

[7]

Downing NR, Williams JK, Daack-Hirsch S, Driessnack M, Simon CM. Genetics specialists’ perspectives on disclosure of genomic incidental findings in the clinical setting. Patient Educ Couns 2013;90(1):133-8. https://www.sciencedirect.com/science/article/pii/S0738399112003837?casa_token=giR11F1rz_wAAAAA:jt3cd371ip393YC4k31nyRLpBkdKZYKp38_eacO8grqVUI9NiXZpj3zRlYAuoiNmQT76dr2l6g.https://www.sciencedirect.com/science/article/pii/S0738399112003837?casa_token=giR11F1rz_wAAAAA:jt3cd371ip393YC4k31nyRLpBkdKZYKp38_eacO8grqVUI9NiXZpj3zRlYAuoiNmQT76dr2l6g

[8]

Gray SW, Hicks-Courant K, Lathan CS, Garraway L, Park ER, Weeks JC. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. J Oncol Pract 2012;8(6):329 − 35. http://dx.doi.org/10.1200/JOP.2012.000626 CrossRef

[9]

Mighton C, Carlsson L, Clausen M, Casalino S, Shickh S, McCuaig L, et al. Development of patient “profiles” to tailor counseling for incidental genomic sequencing results. Eur J Hum Genet 2019;27(7):1008-17. https://www.nature.com/articles/s41431-019-0352-2.https://www.nature.com/articles/s41431-019-0352-2

[10]

Hufnagel SB, Martin LJ, Cassedy A, Hopkin RJ, Antommaria AHM. Adolescents’ preferences regarding disclosure of incidental findings in genomic sequencing that are not medically actionable in childhood. Am J Med Genet Part A 2016;170(8):2083-8. https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.a.37730?casa_token=hngBVly5T5YAAAAA%3AbHiE-sUB0vnvDH7H3AJ-gi9lEHo4xeoYlgZcAw2DWqJKm_toHi23YtA95GKamehT5NQtDtUmbjyYTg.https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.a.37730?casa_token=hngBVly5T5YAAAAA%3AbHiE-sUB0vnvDH7H3AJ-gi9lEHo4xeoYlgZcAw2DWqJKm_toHi23YtA95GKamehT5NQtDtUmbjyYTg

[11]

Knoppers BM, Zawati MH, Sénécal K. Return of genetic testing results in the era of whole-genome sequencing. Nat Rev Genet 2015;16(9):553-9. https://www.nature.com/articles/nrg3960.https://www.nature.com/articles/nrg3960

[12]

Miller DT, Lee K, Chung WK, Gordon AS, Herman GE, Klein TE, et al. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021;23(8):1381-90. https://www.nature.com/articles/s41436-021-01172-3.https://www.nature.com/articles/s41436-021-01172-3

[13]

Boycott K, Hartley T, Adam S, Bernier F, Chong KR, Fernandez BA, et al. The clinical application of genome-wide sequencing for monogenic diseases in Canada: position statement of the Canadian college of medical geneticists. J Med Genet 2015;52(7):431-7. https://jmg.bmj.com/content/52/7/431.short.https://jmg.bmj.com/content/52/7/431.short

[14]

Khoury MJ, Armstrong GL, Bunnell RE, Cyril J, Iademarco MF. The intersection of genomics and big data with public health: opportunities for precision public health. PLoS Med 2020;17(10):e1003373. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003373.https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003373

[15]

Khoury MJ, Bowen MS, Clyne M, Dotson WD, Gwinn ML, Green RF, et al. From public health genomics to precision public health: a 20-year journey. Genet Med 2018;20(6):574-82. https://www.sciencedirect.com/science/article/pii/S1098360021010042.https://www.sciencedirect.com/science/article/pii/S1098360021010042

[16]

Knoppers BM, Zawati MH, Senecal K. Senecal K. Return of genetic testing results in the era of whole-genome sequencing. Nature Reviews Genetics 2015;16(9):553 − 9. http://dx.doi.org/10.1038/nrg3960 CrossRef

[17]

Weiner C. Anticipate and communicate: ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). Am J Epidemiol 2014;180(6):562-4. https://academic.oup.com/aje/article/180/6/562/2739282?login=true.https://academic.oup.com/aje/article/180/6/562/2739282?login=true

[18]

ACMG Board of Directors. Points to consider for informed consent for genome/exome sequencing. Genet Med 2013;15(9):748-9. https://pubmed.ncbi.nlm.nih.gov/23970068/.https://pubmed.ncbi.nlm.nih.gov/23970068/

[19]

Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15(7):565-74. https://pubmed.ncbi.nlm.nih.gov/23788249/.https://pubmed.ncbi.nlm.nih.gov/23788249/

[20]

ACMG Board of Directors. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med 2015;17(1):68-9. https://pubmed.ncbi.nlm.nih.gov/25356965/.https://pubmed.ncbi.nlm.nih.gov/25356965/

[21]

Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017;19(2):249-55. https://pubmed.ncbi.nlm.nih.gov/27854360/.https://pubmed.ncbi.nlm.nih.gov/27854360/

[22]

Van El CG, Cornel MC, Borry P, Hastings RJ, Fellmann F, Hodgson SV, et al. Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. Eur J Hum Genet 2013;21(6):580-4. https://pubmed.ncbi.nlm.nih.gov/23676617/.https://pubmed.ncbi.nlm.nih.gov/23676617/

[23]

Hall A, Finnegan T, Alberg C. Realising genomics in clinical practice. 2014. https://www.phgfoundation.org/media/173/download/Realising-genomics-clinical-practice-executive-summary.pdf?v=1&inline=1. [2021-3-31]. https://www.phgfoundation.org/media/173/download/Realising-genomics-clinical-practice-executive-summary.pdf?v=1&inline=1

[24]

Middleton A, Patch C, Wiggins J, Barnes K, Crawford G, Benjamin C, et al. Position statement on opportunistic genomic screening from the Association of Genetic Nurses and Counsellors (UK and Ireland). Eur J Human Genet 2014;22(8):955-6. https://www.nature.com/articles/ejhg2013301.https://www.nature.com/articles/ejhg2013301

[25]

Ethikrat D. The future of genetic diagnosis—from research to clinical practice. 2013. https://www.ethikrat.org/fileadmin/Publikationen/Stellungnahmen/englisch/opinion-the-future-of-genetic-diagnosis.pdf. [2021-3-31]. https://www.ethikrat.org/fileadmin/Publikationen/Stellungnahmen/englisch/opinion-the-future-of-genetic-diagnosis.pdf

[26]

Royal College of Pathologists of Australasia. Implementation of massively parallel sequencing in diagnostic medical genetic testing 2013. https://www.hgsa.org.au/hgsanews/guidelines-for-implementation-of-massively-parallel-sequencing.https://www.hgsa.org.au/hgsanews/guidelines-for-implementation-of-massively-parallel-sequencing

[27]

Howard HC, Knoppers BM, Cornel MC, Clayton EW, Sénécal K, Borry P, et al. Whole-genome sequencing in newborn screening? A statement on the continued importance of targeted approaches in newborn screening programmes. Eur J Hum Genet 2015;23(12):1593-600. https://pubmed.ncbi.nlm.nih.gov/25626707/.https://pubmed.ncbi.nlm.nih.gov/25626707/

[28]

Biesecker LG. Incidental variants are critical for genomics. Am J Hum Genet 2013;92(5):648-51. https://pubmed.ncbi.nlm.nih.gov/23643378/.https://pubmed.ncbi.nlm.nih.gov/23643378/

[29]

Okbay A, Baselmans BML, De Neve JE, Turley P, Nivard MG, Fontana MA, et al. Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nat Genet 2016;48(6):624-33. https://pubmed.ncbi.nlm.nih.gov/27089181/.https://pubmed.ncbi.nlm.nih.gov/27089181/

[30]

Lu J, Jiang S, Wang Y, Zhang N, Jiao G. PNS41 preferences of older patients with chronic diseases for medication review services in Shanxi, China: results from a discrete choice experiment. Value Heal Reg Issues 2020;22(S1):S88. https://www.valuehealthregionalissues.com/article/S2212-1099(20)30509-4/fulltext.https://www.valuehealthregionalissues.com/article/S2212-1099(20)30509-4/fulltext

[31]

Liu P, Jiang S, Li SP. Systematic review of measuring the preference for targeted therapy in cancer patients by discrete choice experiment. Chin J Cancer Prev Treat 2021;28(4):318-22. https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjIwNzE5Eg9xbHpsenoyMDIxMDQwMTMaCDliamdqb2Rp. (In Chinese). https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjIwNzE5Eg9xbHpsenoyMDIxMDQwMTMaCDliamdqb2Rp

[32]

Zhang LF, Huang JJ, Wang H, Jiang S. An overview on theoretic and applied research of best-worst scaling. Stat Inf Forum 2019;34(3):24-30. https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjIwNzE5EhB0anl4eGx0MjAxOTAzMDA0GggxcXprd3Uyag%3D%3D. (In Chinese). https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3UzIwMjIwNzE5EhB0anl4eGx0MjAxOTAzMDA0GggxcXprd3Uyag%3D%3D

[33]

Jiang S, Lu J. PNS20 best-worst scaling in health economics in China: past, present and future. Value Health 2020;23(S1):S287. https://www.valueinhealthjournal.com/article/S1098-3015(20)31219-5/fulltext.https://www.valueinhealthjournal.com/article/S1098-3015(20)31219-5/fulltext

[34]

Jiang S, Gu YY, Yang F, Wu T, Wang H, Cutler H, et al. Tertiary hospitals or community clinics? An enquiry into the factors affecting patients' choice for healthcare facilities in urban China. China Econ Rev 2020;63:101538. https://www.sciencedirect.com/science/article/pii/S1043951X20301358?casa_token=PFothgKNYVAAAAAA:T_sTmyrOoqIfMW_w-jjVAIy2KRciCfVEtef52K2HrzcHXwZLr2IKCbC7HnFMvh0UBI2P3f28wQ.https://www.sciencedirect.com/science/article/pii/S1043951X20301358?casa_token=PFothgKNYVAAAAAA:T_sTmyrOoqIfMW_w-jjVAIy2KRciCfVEtef52K2HrzcHXwZLr2IKCbC7HnFMvh0UBI2P3f28wQ

[35]

Scheuner MT, Peredo J, Benkendorf J, Bowdish B, Feldman G, Fleisher L, et al. Reporting genomic secondary findings: ACMG members weigh in. Genet Med 2015;17(1):27-35. https://www.nature.com/articles/gim2014165.https://www.nature.com/articles/gim2014165

[36]

Regier DA, Peacock SJ, Pataky R, Van Der Hoek K, Jarvik GP, Hoch J, et al. Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment. CMAJ 2015;187(6):E190-7. https://pubmed.ncbi.nlm.nih.gov/25754703/.https://pubmed.ncbi.nlm.nih.gov/25754703/

[37]

Liu XQ, Luo X, Jiang CY, Zhao H. Difficulties and challenges in the development of precision medicine. Clin Genet 2019;95(5):569-74. https://onlinelibrary.wiley.com/doi/abs/10.1111/cge.13511?casa_token=p4n6-XRcSmoAAAAA:jNU6e3HXO0IYXq1m3m89lLSa9YV-bK-i1a0wK_Ao8DCFWDVpZM1O3JnqPIeJwkGBQ2BnZLafg2hvqrG_.https://onlinelibrary.wiley.com/doi/abs/10.1111/cge.13511?casa_token=p4n6-XRcSmoAAAAA:jNU6e3HXO0IYXq1m3m89lLSa9YV-bK-i1a0wK_Ao8DCFWDVpZM1O3JnqPIeJwkGBQ2BnZLafg2hvqrG_

[38]

Xue Y, Lameijer EW, Ye K, Zhang KL, Chang SH, Wang XY, et al. Precision medicine: what challenges are we facing? Genom Proteom Bioinform 2016;14(5):253-61. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093857/.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093857/

[39]

Jiang S, Chen Z, Wu J, Zang X, Jiang YW. Addressing methodological and ethical issues in practicing health economic evaluation in China. J Global Health 2020;10(2):020322. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561214/.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561214/

[40]

Chen Z, Zhou L, Jiang S, Haddix A. Identifying options of best value: use of economic evaluation in public health. China CDC Wkly 2020;2(5):75-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393107/.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393107/

[41]

Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, et al. Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions. Value Health 2018;21(9):1033-42. https://www.sciencedirect.com/science/article/pii/S1098301518322691.https://www.sciencedirect.com/science/article/pii/S1098301518322691

[42]

Jiang S, Wang YT, Zhou JW, Jiang YW, Liu GGE, Wu J. Incorporating future unrelated medical costs in cost-effectiveness analysis in China. BMJ Global Heal 2021;6(10):e006655. https://gh.bmj.com/content/6/10/e006655.abstract.https://gh.bmj.com/content/6/10/e006655.abstract

[43]

Cai D, Shi S, Jiang S, Si L, Wu J, Jiang YW. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ 2022;23(4):607-15. https://link.springer.com/article/10.1007/s10198-021-01384-z.https://link.springer.com/article/10.1007/s10198-021-01384-z